FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul
Executive Summary
FDA's Office of Drug Safety will take on a higher profile position under a proposed reorganization of the Center for Drug Evaluation & Research
You may also be interested in...
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects